Roche agreed to acquire PathAI in a deal valued at up to $1.05 billion to expand its digital pathology and companion diagnostics capabilities. Roche will pay $750 million upfront, with as much as $300 million tied to milestones, and expects to close in the second half of 2026 subject to regulatory approvals. Roche said PathAI’s image-management and AI workflow tooling will be integrated with Roche Diagnostics and its oncology diagnostic platforms. The transaction follows a partnership that began in 2021 and expanded in 2024 toward AI-enabled companion diagnostic algorithm development. The acquisition arrives as digital pathology remains a key investment area for biopharma companies seeking scalable, AI-supported diagnostic and trial enrichment workflows.